Project Grant R21AG085331

Award Date 6/15/24
Completion Date 3/31/26
Dollars Obligated $1M
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
Columbia, SC 29208, USA
Similar Awards
The University of New Mexico Health Sciences Center (UNM HSC) was awarded a 3-year, $2,140,130 Project Grant (CFDA 93.866) from the National Institute on Aging to study the role of endothelial dysfunction in Alzheimer's disease (AD). The project aims to identify novel endothelial biomarkers that can serve as diagnostic and prognostic indicators of brain endothelial dysfunction in AD. Over 3,400 participants from well-characterized longitudinal AD and healthy control cohorts will undergo...
This Project Grant award from the National Institute on Aging (NIA), under CFDA 93.866 Aging Research, provides $715,801 to Duke University to investigate the causal role of blood-brain barrier dysfunction and neuroinflammation in exacerbating postoperative delirium and subsequent onset of Alzheimer's disease and related dementias in aging and hypertension. The overarching goal is to elucidate how hypertension primes the neurovascular unit and worsens delirium-like behavior after orthopedic...
The National Institute on Aging awarded a $480,536 Project Grant under the Aging Research program (CFDA 93.866) to The Jackson Laboratory to fund research aimed at improving treatment for Alzheimer's disease and related dementias (ADRD). The project will assess whether manipulating the angiopoietin/tie2 (ANG/TIE2) signaling pathway can preserve blood-brain barrier (BBB) integrity and prevent cerebrovascular dysfunction, which are major contributors to many ADRDs. The research approach involves...
This Project Grant award of $2,683,965 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) will support the development and optimization of an improved all-human cellular system, or "brain-chip", for studying Alzheimer's disease and related dementias (ADRDs). The key objectives are to: 1) define delivery conditions for introducing patient blood cells and plasma into...
This $705,405 Project Grant awarded by the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) aims to investigate the role of adventitial fibroblasts, an understudied cell population, in the development and progression of atherosclerosis. The key objectives are to: Determine the mechanism by which targeted genetic ablation of adventitial fibroblasts decreases atherosclerotic plaque formation, despite these cells not directly contributing to the intimal...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $772,581 to the University of California, San Diego (UCSD) to investigate the role of the transcription factor SOX18 in neurovascular dysfunction associated with Alzheimer's disease. The research aims to: 1) examine how SOX18 modulates neurovascular function, including angiogenesis and blood-brain barrier formation, in mouse models; 2) use human induced pluripotent stem cell-based in vitro...
This $1,955,041 Project Grant from the National Institutes of Health's National Institute on Aging, under the Aging Research program (CFDA 93.866), will fund research into the relationship between sleep, pericytes, and Alzheimer's disease pathology. The Medical University of South Carolina will investigate whether pericytes, cells that regulate cerebral blood flow and blood-brain barrier permeability, mediate the effects of sleep disruption on Alzheimer's disease progression. Specifically, the...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to gain a mechanistic understanding of the role of cellular senescence in the pathogenesis of Alzheimer's disease (AD). The $460,625 grant will fund research at the University of Massachusetts Medical School to dissect the separate P53/P21 and P16 senescence pathways and their functional consequences in AD using human induced pluripotent stem cell-based models. The 2-year project will produce...
This $3.61 million project grant from the National Institutes of Health's National Institute on Aging will fund research from July 2022 to June 2025 aimed at understanding and addressing neurovascular coupling dysfunction in Alzheimer's disease and Alzheimer's disease-related dementias. Specifically, the University of Colorado Denver will investigate the hypothesis that restoring neurovascular coupling can mitigate synaptic plasticity deterioration in the hippocampus and its behavioral...
The National Institute on Aging awarded a $1,931,965 Project Grant (CFDA 93.866 - Aging Research) to the Regenerative Research Foundation, a non-profit organization in Albany, New York. The purpose of this federal grant is to develop and validate a novel human induced pluripotent stem cell (iPSC) model that incorporates cerebral cortical neurons, glia, vascular endothelial cells, and microglia to study cerebrovascular interactions in Alzheimer's disease-related dementias (ADRD). The R61 phase of...

REPROGRAMMING ENDOTHELIAL CELLS TO PREVENT AND TREAT ALZHEIMER DISEASE (AD) AND HYPERTENSION - PROJECT SUMMARY WENCESLAU, CAMILLA F. GROWING EVIDENCE SUPPORTS A ROBUST AND LIKELY CAUSAL ASSOCIATION BETWEEN CARDIOVASCULAR DISEASE (CVD), AND ITS RISK FACTORS, WITH ALZHEIMER'S DISEASE (AD). HOWEVER, STANDARD PARADIGMS SUCH AS "HEAD TO HEART CONNECTION", WHERE HEART FAILURE LEADS TO CEREBRAL HYPOPERFUSION, NEURONAL DAMAGE AND, SUBSEQUENTLY AD ARE QUESTIONABLE, AND THEY SHOULD BE REVIEWED WITH A CRITICAL APPROACH. HERE, WE CLAIM THAT VASCULAR ENDOTHELIAL CELLS HAVE A CENTRAL ROLE IN THE DEVELOPMENT AND PROGRESSION OF AD AND HYPERTENSION. OVER TIME, AS THE BODY AGES, THE VASCULATURE BECOMES LESS SUSCEPTIBLE TO REPAIR. ONE OF THE REASONS IS AN EXACERBATED ENDOTHELIAL-TO-MESENCHYMAL TRANSITION (ENDMT). ENDMT IS A CELLULAR TRANSDIFFERENTIATION PROGRAM IN WHICH ENDOTHELIAL CELLS PARTIALLY LOSE THEIR IDENTITY AND ACQUIRE MESENCHYMAL CELL- LIKE FEATURES AND THIS REDUCES BLOOD FLOW AND ORGAN PERFUSION. ONE OF THE TRIGGERS OF ENDMT IS ENDOPLASMIC RETICULUM (ER) STRESS, WHICH ALSO RELEASES MISFOLDED PROTEINS, INCLUDING AMYLOID-B PROTEIN OLIGOMERS (ABO), THE MOST POTENT NEUROTOXIN IN AD. HERE, WE OBSERVED THAT 1. DYSFUNCTIONAL VASCULAR TISSUE FROM HUMANS AND RODENTS RELEASES AND SENSES ABO. 2. VASCULAR DYSFUNCTION IS PROMINENT PRIOR TO THE ONSET OF AD. 3. INCREASED PLASMA LEVELS OF ABO ARE PRESENT IN HYPERTENSIVE MICE. 4. ABO INDUCED ER STRESS IN ENDOTHELIAL CELLS AND ER STRESS CAUSED THE FURTHER RELEASE OF ABO, SHOWING A POSITIVE FEEDFORWARD MECHANISM. THESE UNCONVENTIONAL OBSERVATIONS CALL FOR FURTHER ANALYSIS OF THE CAUSATIVE CONNECTION BETWEEN ENDOTHELIAL DYSFUNCTION AND AD. THEREFORE, THE OVERALL GOAL OF THIS EXPLORATORY AND DEVELOPMENTAL GRANTS (R21) PROJECT IS TO REPROGRAM ENDOTHELIAL CELLS FOR THE TREATMENT OF AD AND HYPERTENSION. FOR THIS, WE WILL TEST THE HYPOTHESES THAT THE CAUSE OF AD AND HYPERTENSION IS THE EXACERBATED FORMATION OF ENDMT VIA ER STRESS WHICH INCREASES THE SECRETION OF ABO. BY OVEREXPRESSING YAMANAKA FACTORS (OSK) TO INDUCE PARTIAL CELLULAR REPROGRAMMING, WITHOUT PASSING THROUGH THE PLURIPOTENT STATE, WE WILL REDUCE ENDMT FORMATION TO PREVENT AND REVERSE AD. WE ALSO WANT TO DETERMINE WHETHER ARTERY DYSFUNCTION IN HYPERTENSIVE MICE PRESENT WITH SIMILAR PHENOTYPE SEEN IN AD MICE. THIS PLANNED RESEARCH IS UNIQUELY SUITED TO THE R21 PROGRAM, RATHER THAN TO A TRADITIONAL GRANT (E.G., R01), BECAUSE IT EXPLORES AND OPENS A NEW AREA OF RESEARCH IN MY LABORATORY, BY STUDYING ENDMT AND YAMANAKA FACTORS AS THE UNDERPINNING OF AD. IF OUR HYPOTHESIS IS CORRECT, THIS PROJECT WILL PRODUCE A MAJOR IMPACT ON AD AND CVD.

Posted 6/4/24, 12:00 AM